Cabozantinib for Patients With Recurrent or Progressive Meningioma

Study overview

A Phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Collaborators and Investigators

Baptist Health South Florida,

Yazmin Odia, M.D., PRINCIPAL_INVESTIGATOR, Miami Cancer Institute at Baptist Health, Inc.

Study Record Dates

2028-05